Treatment of Fabry patients > 18 years with enzyme supplementation therapy: comparison of efficacy and toxicity of low dose (0,2 mg/kg) fabrazyme (agalsidase beta) or replagal (agalsidase alfa).
Completed
- Conditions
- Fabry disease.
- Registration Number
- NL-OMON24907
- Lead Sponsor
- Sponsor: College voor Zorgverzekeringen (dutch health care insurance board).Initiator:Dr. C.E.M. Hollak, internistDept. of Internal Medicine, F4-279Academic Medical CenterPO box 226601100 DD AmsterdamThe Netherlandstel. +31-20-5666071fax: +31-20-6919743e-mail: c.e.hollak@amc.uva.nl
- Brief Summary
PLoS ONE. 2007 Jul 11;2(7):e598.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
1. The patient must have given written informed consent;
2. Patients must be 18 years or older;
Exclusion Criteria
1. Patient is pregnant or lactating;
2. Patient is unwilling to comply to the evaluation program.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method